CooperCompanies Announces CooperVision Has Received FDA Approval of MiSight® for the Treatment of Myopia in Children
CooperCompanies Announces CooperVision Has Received FDA Approval of MiSight® for the Treatment of Myopia in Children
“MiSight is a revolutionary product that can make a meaningful difference in the lives of children needing visual correction,” said President and CEO
Additional information may be found on CooperVision.com and in the CooperVision MiSight press release.
1 MiSight™ (omafilcon A) daily wear single use Soft Contact Lenses are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
2 When compared to the children in the control group wearing a single vision 1-day contact lens.
About CooperCompanies
CooperCompanies ("Cooper") is a global medical device company publicly traded on the
Forward-Looking Statements
This press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Statements relating to guidance, plans, prospects, goals, strategies, future actions, events or performance and other statements of which are other than statements of historical fact, and all statements regarding MiSight and its future availability, acquisitions including the acquired companies’ financial position, market position, product development and business strategy, expected cost synergies, expected timing and benefits of the transaction, difficulties in integrating entities or operations, as well as estimates of our and the acquired entities’ future expenses, sales and diluted earnings per share are forward-looking. In addition, all statements regarding anticipated growth in our revenue, anticipated effects of any product recalls, anticipated market conditions, planned product launches or approvals and expected results of operations and integration of any acquisition are forward-looking. To identify these statements, look for words like "believes," "outlook," "probable," "expects," "may," "will," "should," "could," "seeks," "intends," "plans," "estimates" or "anticipates" and similar words or phrases. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Events that could cause our actual results and actions of the Company to differ from those described in forward-looking statements are described in our
Contact:
Vice President, Investor Relations and Administration
925-460-3663
ir@cooperco.com
Source: The Cooper Companies, Inc.